文献速递炎症性肠病

中性粒细胞调节剂ADS051在溃疡性结肠炎中的安全性、药代动力学和临床疗效:一项随机1b期试验结果

Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial.
PubMed 文献 · Am J Gastroenterol · 2024-12-31

这项1b期多剂量试验纳入24例中重度溃疡性结肠炎患者,按3:1随机接受ADS051 200 mg、800 mg或3200 mg或安慰剂口服每日一次共28天。ADS051耐受良好,无重度或严重不良事件,粪便浓度高而全身暴露低,第28天临床缓解率22.2% vs 0%、内镜应答率50.0% vs 16.7%、内镜改善率33.3% vs 0%。

要点

  • ADS051耐受良好,未发生重度或严重不良事件。
  • 粪便浓度高而全身暴露低,尿中排泄<1%的日剂量。
  • 第28天临床缓解22.2% vs 0%,内镜应答50.0% vs 16.7%,内镜改善33.3% vs 0%。

核心结论

  • 1b期数据显示ADS051在溃疡性结肠炎患者中安全性良好,并出现令人鼓舞的临床活性信号,支持推进至2期试验。

研究设计与样本

  • 这项1b期多剂量试验纳入24例中重度溃疡性结肠炎患者,分3个序贯递增剂量队列,按3:1随机接受ADS051 200 mg、800 mg或3200 mg或安慰剂,口服每日一次共28天。

主要发现

  • ADS051耐受良好,未发生重度或严重不良事件。
  • 达到高粪便浓度和低全身暴露,尿中排泄的ADS051低于日剂量的1%。
  • 第28天,汇总ADS051组临床缓解率为22.2%,汇总安慰剂组为0%。
  • 内镜应答率在ADS051给药组为50.0%,安慰剂组为16.7%;内镜改善率在ADS051给药组为33.3%,安慰剂组为0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ulcerative colitis (UC) is characterized by colonic inflammation, with neutrophils playing a key role in UC activity, prognosis, and response to therapies. Current UC therapeutics can have significant side effects and limited efficacy. ADS051 is a novel, oral, gut-restricted small molecule that modulates neutrophil migration and activation without in vitro suppression of T-cell activation. The primary objective of this Phase 1b multidose trial was to evaluate the safety of ADS051. Secondary objectives were clinical activity and pharmacokinetics assessment. METHODS: This trial enrolled 24 patients with moderate-to-severe UC in 3 sequential ascending dose cohorts with 3:1 randomization to ADS051 200 mg, 800 mg, or 3,200 mg, or placebo, administered orally once daily for 28 days. Safety, tolerability, and pharmacokinetics were assessed weekly, with clinical activity end points of clinical remission, endoscopic improvement, and histologic remission evaluated at Day 28. RESULTS: ADS051 was well tolerated without severe or serious adverse events. High fecal concentrations were achieved with low systemic exposure, with <1% of the daily dose of ADS051 excreted in urine. On Day 28 of the trial, clinical remission was achieved in 22.2% of the pooled ADS051 group vs 0% of the pooled placebo group. Endoscopic response was achieved in 50.0% of ADS051-dosed vs 16.7% of placebo, and endoscopic improvement was achieved in 33.3% of ADS051-dosed vs 0% of placebo. DISCUSSION: Phase 1b data in patients with UC indicate a favorable safety profile for ADS051 with encouraging signals of clinical activity, supporting the advancement to a Phase 2 trial.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Allegretti JR, Cheifetz AS, Dulai PS, et al. Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial. Am J Gastroenterol. 2024. PMID: 39787364. doi:10.14309/ajg.0000000000003269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。